Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure.
BACKGROUND: Elevated plasma norepinephrine levels are associated with increased mortality in patients and in animal models with chronic heart failure. To test which alpha2-adrenoceptor subtypes operate as presynaptic inhibitory receptors to control norepinephrine release in heart failure, we invest...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2002
|
| _version_ | 1797079567178924032 |
|---|---|
| author | Brede, M Wiesmann, F Jahns, R Hadamek, K Arnolt, C Neubauer, S Lohse, M Hein, L |
| author_facet | Brede, M Wiesmann, F Jahns, R Hadamek, K Arnolt, C Neubauer, S Lohse, M Hein, L |
| author_sort | Brede, M |
| collection | OXFORD |
| description | BACKGROUND: Elevated plasma norepinephrine levels are associated with increased mortality in patients and in animal models with chronic heart failure. To test which alpha2-adrenoceptor subtypes operate as presynaptic inhibitory receptors to control norepinephrine release in heart failure, we investigated the response of gene-targeted mice lacking alpha2-adrenoceptor subtypes (alpha2-KO) to chronic left ventricular pressure overload. In addition, we determined the functional consequences of genetic variants of alpha2-adrenoceptors in human patients with chronic heart failure. METHODS AND RESULTS: Cardiac pressure overload was induced by transverse aortic constriction. Three months after aortic banding, survival was dramatically reduced in alpha2A-KO (52%) and alpha2C-KO (47%) mice compared with wild-type and alpha2B-deficient (86%) animals. Excess mortality in alpha2A- and alpha2C-KO strains was attributable to heart failure with enhanced left ventricular hypertrophy and fibrosis and elevated circulating catecholamines. The clinical importance of this finding is emphasized by the fact that heart failure patients with a dysfunctional variant of the alpha2C-adrenoceptor had a worse clinical status and decreased cardiac function as determined by invasive catheterization and by echocardiography. CONCLUSIONS: Our results indicate an essential function of alpha2A- and alpha2C-adrenoceptors in the prevention of heart failure progression in mice and human patients. Identification of heart failure patients with genetic alpha2-adrenoceptor variants as well as new alpha2-receptor subtype-selective drugs may represent novel therapeutic strategies in chronic heart failure and other diseases with enhanced sympathetic activation. |
| first_indexed | 2024-03-07T00:47:47Z |
| format | Journal article |
| id | oxford-uuid:8548d481-c40a-4d7f-a424-e559b8eb1b0b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:47:47Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:8548d481-c40a-4d7f-a424-e559b8eb1b0b2022-03-26T21:56:31ZFeedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8548d481-c40a-4d7f-a424-e559b8eb1b0bEnglishSymplectic Elements at Oxford2002Brede, MWiesmann, FJahns, RHadamek, KArnolt, CNeubauer, SLohse, MHein, L BACKGROUND: Elevated plasma norepinephrine levels are associated with increased mortality in patients and in animal models with chronic heart failure. To test which alpha2-adrenoceptor subtypes operate as presynaptic inhibitory receptors to control norepinephrine release in heart failure, we investigated the response of gene-targeted mice lacking alpha2-adrenoceptor subtypes (alpha2-KO) to chronic left ventricular pressure overload. In addition, we determined the functional consequences of genetic variants of alpha2-adrenoceptors in human patients with chronic heart failure. METHODS AND RESULTS: Cardiac pressure overload was induced by transverse aortic constriction. Three months after aortic banding, survival was dramatically reduced in alpha2A-KO (52%) and alpha2C-KO (47%) mice compared with wild-type and alpha2B-deficient (86%) animals. Excess mortality in alpha2A- and alpha2C-KO strains was attributable to heart failure with enhanced left ventricular hypertrophy and fibrosis and elevated circulating catecholamines. The clinical importance of this finding is emphasized by the fact that heart failure patients with a dysfunctional variant of the alpha2C-adrenoceptor had a worse clinical status and decreased cardiac function as determined by invasive catheterization and by echocardiography. CONCLUSIONS: Our results indicate an essential function of alpha2A- and alpha2C-adrenoceptors in the prevention of heart failure progression in mice and human patients. Identification of heart failure patients with genetic alpha2-adrenoceptor variants as well as new alpha2-receptor subtype-selective drugs may represent novel therapeutic strategies in chronic heart failure and other diseases with enhanced sympathetic activation. |
| spellingShingle | Brede, M Wiesmann, F Jahns, R Hadamek, K Arnolt, C Neubauer, S Lohse, M Hein, L Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. |
| title | Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. |
| title_full | Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. |
| title_fullStr | Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. |
| title_full_unstemmed | Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. |
| title_short | Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. |
| title_sort | feedback inhibition of catecholamine release by two different alpha2 adrenoceptor subtypes prevents progression of heart failure |
| work_keys_str_mv | AT bredem feedbackinhibitionofcatecholaminereleasebytwodifferentalpha2adrenoceptorsubtypespreventsprogressionofheartfailure AT wiesmannf feedbackinhibitionofcatecholaminereleasebytwodifferentalpha2adrenoceptorsubtypespreventsprogressionofheartfailure AT jahnsr feedbackinhibitionofcatecholaminereleasebytwodifferentalpha2adrenoceptorsubtypespreventsprogressionofheartfailure AT hadamekk feedbackinhibitionofcatecholaminereleasebytwodifferentalpha2adrenoceptorsubtypespreventsprogressionofheartfailure AT arnoltc feedbackinhibitionofcatecholaminereleasebytwodifferentalpha2adrenoceptorsubtypespreventsprogressionofheartfailure AT neubauers feedbackinhibitionofcatecholaminereleasebytwodifferentalpha2adrenoceptorsubtypespreventsprogressionofheartfailure AT lohsem feedbackinhibitionofcatecholaminereleasebytwodifferentalpha2adrenoceptorsubtypespreventsprogressionofheartfailure AT heinl feedbackinhibitionofcatecholaminereleasebytwodifferentalpha2adrenoceptorsubtypespreventsprogressionofheartfailure |